Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
We now rank 3rd in pharmaceutical production by volume and 14th by value
Subscribe To Our Newsletter & Stay Updated